KEAP1 and ovarian carcinoma: The expression level of P62 in cisplatin-resistant human ovarian cancer cells is much higher than that in cisplatin-sensitive cells, and cisplatin resistance is acquired through regulating the keap1-NRF2-ARE signal pathway.